Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects With an Alcohol Use Disorder Who Are Experiencing Insomnia Associated With Alcohol Cessation

Next Previous
Trial Profile

A Phase 2, Randomized, Double-Blind, Multi-Center, Placebo-Controlled, Parallel-Group Study to Evaluate the Safety, Tolerability, and Efficacy of V117957 in Subjects With an Alcohol Use Disorder Who Are Experiencing Insomnia Associated With Alcohol Cessation

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunobinop (Primary)
  • Indications Insomnia
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Imbrium Therapeutics

Most Recent Events

  • 12 Dec 2022 According to an Imbrium Therapeutics media release, Nelson Sessler, is the lead author on the study.
  • 12 Dec 2022 Primary endpoint has been met. (Change from baseline of wakefulness after sleep onset (WASO) measured by polysomnography (PSG)), according to an Imbrium Therapeutics media release.
  • 12 Dec 2022 Preliminary results published in the Imbrium Therapeutics Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top